36C25719Q0276-000.docx

FedBizOpps Sources Sought Notice

CLASSIFICATION CODE

SUBJECT

CONTRACTING OFFICE'S

ZIP-CODE

SOLICITATION NUMBER

RESPONSE DATE (MM-DD-YYYY)

ARCHIVE

DAYS AFTER THE RESPONSE DATE

RECOVERY ACT FUNDS

SET-ASIDE

NAICS CODE

CONTRACTING OFFICE

ADDRESS

POINT OF CONTACT

(POC Information Automatically Filled from User Profile Unless Entered)

DESCRIPTION

See Attachment

AGENCY'S URL

URL DESCRIPTION

AGENCY CONTACT'S EMAIL

ADDRESS

EMAIL DESCRIPTION

ADDRESS

POSTAL CODE

COUNTRY

ADDITIONAL INFORMATION

GENERAL INFORMATION

PLACE OF PERFORMANCE

* = Required Field FedBizOpps Sources Sought Notice Rev. March 2010 NTX Kaneka LDL Apheresis Unit 549-19-1-205-0137 78229 36C25719Q0276 01-29-2019 N 325414 Department of Veterans Affairs VISN17 Network Contracting Activity 7400 Merton Minter Blvd. (10N17/90C) San Antonio TX 78229 Susan Flores Susan.flores2@va.gov Dallas VAMC 4500 South Lancaster Road Dallas, TX 75216-1329 75216

USA

Susan.flores2va.gov Susan.flores2va.gov Susan.flores2va.gov

DISCLAIMER

This RFI is issued solely for information and planning purposes only and does not constitute a solicitation. All information received in response to this RFI that is marked as proprietary will be handled accordingly. In accordance with FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI.

This Sources Sought Notice is for informational and planning purposes only and shall not be construed as a solicitation or as an obligation or commitment by the Government. This notice is intended strictly for Market Research. This is a Request for Information ONLY. This is NOT a solicitation for proposals, proposal abstracts, or quotations.

The Department of Veterans Affairs Dallas VA Medical Center in Dallas, Texas intends to award a firm-fixed price contract, for the purchase of LDL Apheresis Unit. (See attached salient characteristics for more information).

The Government is conducting a market survey to help determine the availability and technical capability of qualified service-disabled veteran-owned small businesses, veteran-owned small businesses, small businesses, HUBZone small businesses and/or other large businesses capable of serving the needs identified below. This notice of intent is for open market as well as Federal Supply Schedule items.

The purpose of this notice is to gain knowledge of potential qualified sources and their size classification/socioeconomic status (service-disabled veteran owned small business, veteran owned small business, women-owned small business, HUB Zone, 8(a), small business or large business, relative to NAICS 325414. Responses to this notice will be used by the Government to make appropriate acquisition decisions. A solicitation is not currently available. If a solicitation is issued, it will be announced on Federal Business opportunities website http://www.fbo.gov or GSA E-Buy at a later date, and all interested parties must respond to that solicitation announcement separately from the responses to this announcement.

***Brand-name only. *** Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible.

Please advise if you carry the products for this requirement. Please submit all information to Susan Flores at susan.flores@va.gov no later than January 29, 2019, 12 AM ET (11 AM CT).

Salient Characteristics:

The system is comprised of a tubing set, two blood filters, two blood storage columns, and a computer that controls the entire system.

LIPOSORBER LA-15 System – integrated, automated extracorporeal blood processing system with displosables and control/monitor machine including:

Liposorber LA-15 Columns Sulflux KP-05 Plasma Separators (per case of 6) NK-M3R (U) Tubing Sets for Plasmapheresis (Exclusively for MA--3 LDL Aphersesis Unit) (per case of 6) MA-03 LDL Apheresis Unit

Physician and Patient Benefits Liposorber removes harmful (LDL) cholesterol in patients who are unresponsive to cholesterol lowering medications. Such patients have no options other than undergo repetitive life-saving cholesterol removal via the Liposorber filter. Without such treatment affected patients face repeated heart attacks and premature death. It is FDA approved for this indication. Libosorber filtration of bad cholesterol is FFDA approved for removal of bad cholesterol in patients who have had heart attacks and despite medications have bad cholesterol levels >190 mg/dL.

Place of Performance: Dallas VA Medical Center at 4500 S. Lancaster Rd. Dallas TX 75216.

image1.png